Novel peptide compound
AssigneesInternational Institute of Cancer Immunology, Inc., Chugai Seiyaku Kabushiki Kaisha, Dainippon Sumitomo Pharma Co., Ltd.
InventorsToshio Nishihara, Masashi Gotoh
Life of this patent
Estimating the term…
Abstract
A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.
Claims16
A compound of the formula (1):
- wherein X is a tyrosine residue or a methionine residue;
- each of Y and Z is independently selected from a single bond and a divalent peptide group consisting of 1-10 amino acid residues,
- R1 is hydrogen or alkyl,
- R2 is hydroxyl, amino, alkylamino or dialkylamino,
- R3 is hydrogen, alkyl, amino, alkylamino, dialkylamino or substituted or unsubstituted alkylcarbonylamino,
- R4 is hydrogen, alkyl, carboxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl or a group of the formula (2):
- wherein W is an amino acid residue,
- m is 1 or 2, and
- n is an integer of 0-2, with the proviso that when n is 0, R3 is hydrogen or alkyl,
- or a pharmaceutically acceptable salt thereof
A compound of the formula (1′):
- wherein X′ is a tyrosine residue or a methionine residue,
- R1 is hydrogen or alkyl,
- R2′ is hydroxyl, amino, alkylamino or dialkylamino,
- R3′ is amino, alkylamino, dialkylamino or substituted or unsubstituted alkylcarbonylamino, and
- R4′ is carboxy, carbamoyl, alkylcarbamoyl or dialkylcarbamoyl, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.